NeoGenomics Laboratories Claimed Company

NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, and more. read more

EMPLOYEE PARTICIPANTS: 54

TOTAL RATINGS: 503

CEO: Doug VanOort

HR or Marketing? Claim Your Free Employer Account

Doug VanOort NeoGenomics Laboratories CEO Rating

NeoGenomics Laboratories' CEO, Doug VanOort, has 39 employee ratings and a score of 75/100, placing them in the Top 20% of similar size companies on Comparably with 501-1,000 Employees. When breaking the CEO score down by factors such as department, gender, and ethnicity, we see that females at NeoGenomics Laboratories rate Doug VanOort higher than males, giving the CEO a score of 97/100.

Last updated 13 days ago.

Where This Score Ranks NeoGenomics Laboratories' CEO Rating

TOP
20%
In the Top 20% of 1832 Similar Sized Companies on Comparably
1st
1st place versus 3 competitors rated on Comparably

Jan

Mar

Apr

Jan

B+75 / 100

May

NeoGenomics Laboratories CEO Doug VanOort Bio

Doug VanOort serves as the CEO / President of NeoGenomics Laboratories.

Who Ranks NeoGenomics Laboratories' CEO Rating the Highest?

Gender - Female 97/100

Department - HR 96/100

Ethnicity - Caucasian 94/100

Who Ranks NeoGenomics Laboratories' CEO Rating the Lowest?

Gender - Male 57/100

Experience - 6 to 10 Years 75/100

Experience - 3 to 6 Years 83/100

NeoGenomics Laboratories CEO Doug VanOort At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at NeoGenomics Laboratories.

Based on 39 ratings, Doug VanOort ranks right above Foundation Medicine's CEO, Dan Malarek.

NeoGenomics Laboratories' CEO is highly regarded by Female employees, the HR department, and Caucasian employees. However, Male employees, employees with 6 to 10 Years experience, and employees with 3 to 6 Years experience have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.